ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: A recent study has discovered a potent pan-inhibitor of BCR-ABL kinase capable of inhibiting the T315I-resistant mutant [36], its feasibility to enter clinical development for potential use in CML treatment still requires further study.